Quantcast

Industry news that matters to you.  Learn more

Metamark Genetics and HistoRX Announce Licensing Agreement for AQUA Technology

Reading time: 1 – 2 minutes

Metamark Genetics, Inc., a privately held molecular diagnostics company focused on oncology, and HistoRx, Inc., a tissue-based diagnostics company, yesterday announced a multi-year licensing agreement. Metamark has been granted a worldwide license to the AQUA technology by HistoRx for the clinical commercialization of Metamark’s proprietary MetamarkDx Prognostic Assays.

Utilizing fluorescence-labeled antibodies and molecular markers to maximize dynamic range and sensitivity, AQUA technology is an automated image analysis platform that brings objective results to the multiparametric analysis of protein in tissues. AQUA provides results that are quantitative, standardized and reproducible, high-resolution, discretely localized and multiplex-capable.

MetamarkDx diagnostic assays are based on Metamark’s proprietary Prognosis Determinant Discovery Platform.

Mark Straley, President and Chief Executive Officer of Metamark, said:

We are delighted to be working with HistoRx and are eager to develop and validate clinical diagnostics for key biomarkers using the AQUA technology, and to ultimately commercialize them for the benefit of patients around the world. Metamark’s powerful Prognosis Determinants technology, and the multimarker assay panels developed from it, requires objective and reproducible quantitative measurement of protein biomarkers – something specifically enabled by HistoRx’s AQUA technology.

Source: Metamark Genetics